Organogenesis faces a binary risk profile driven by its heavy reliance on Medicare reimbursement codes, which creates extreme quarterly revenue fluctuations such as the 57.1% contraction seen in 2026Q1. While the company maintains a conservative capital struct...
Price trend, volume and key moving averages
Trailing total returns as of 10/10/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.71-102.9% vs -$0.35 | $44M-19.4% vs $54M |
Q2 2026 May 7, 2026 | -$0.37-27.6% vs -$0.29 | $36M-16.2% vs $43M |
Q1 2026 Feb 26, 2026 | $0.31+44.2% vs $0.21 | $225M+30.4% vs $173M |
Q4 2025 Nov 6, 2025 | $0.18-14.3% vs $0.21 | $151M-12.6% vs $173M |
Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth quarter — and therefore good bets to bounce back in the new year
BlackRock Inc. acquired a new position in Organogenesis (NASDAQ: ORGO) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 7,249,528 shares of the company's stock, valued at approximately $17,616,000. BlackRock Inc. owned 5.63% of Organogenesis as of its most recent
Organogenesis NASDAQ: ORGO reported a sharp year-over-year decline in second-quarter revenue as the skin substitute market continued to adjust to coverage and payment changes from the Centers for Medicare & Medicaid Services, while management pointed to sequential improvement in product sales and market share gains.
Organogenesis Holdings Inc. (ORGO) Q2 2026 Earnings Call Transcript
Benchmark ORGO against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Organogenesis Holdings Inc. (ORGO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.28 | $164.7M | 8.53 | 16.8% | 6.58% | 9.04% | — | |
| $4.62 | $673.41M | 14.44 | 19.99% | 1.76% | 2.61% | — | |
| $14.22 | $1.65B | -11.66 | 8.28% | -21.25% | -44% | — | |
| $1.05 | $46.98M | -1.27 | 15.84% | -51.53% | — | — | |
| $40.77 | $850.8M | 16.18 | 3.21% | 4.68% | 13.03% | — | |
| $43.30 | $7.2B | -18.19 | 33.87% | -64.64% | -110.84% | — |
Organogenesis Holdings Inc. (ORGO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Organogenesis Holdings Inc. (ORGO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Aug 6, 2026·SEC
Jun 16, 2026·SEC
Get notified when ORGO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Organogenesis Holdings Inc. (ORGO) stock FAQ — growth, dividends, profitability & financials explained
Organogenesis Holdings Inc. (ORGO) reported $456.5M in revenue for fiscal year 2025.
Organogenesis Holdings Inc. (ORGO) grew revenue by 16.8% over the past year. This is strong growth.
Organogenesis Holdings Inc. (ORGO) reported a net loss of $90.2M for fiscal year 2025.
Organogenesis Holdings Inc. (ORGO) has a return on equity (ROE) of 9.0%. This is below average, suggesting room for improvement.
Organogenesis Holdings Inc. (ORGO) generated $20.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
